Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial

Journal:

Chest

Published:

2026-03-25

DOI:

10.1016/j.chest.2026.02.035

Affiliations:

23

Authors:

25

Go to article

Institutions	Authors	Share
State Key Laboratory of Respiratory Disease (SKLRD), China	3.500000	0.14
Guangzhou Laboratory, China	1.500000	0.06
Nuance Pharma, China	1.000000	0.04
Qingyuan People's Hospital, China	1.000000	0.04
Jiangxi Provincial People's Hospital, China	1.000000	0.04
The General Hospital, TMU, China	1.000000	0.04
Cangzhou People's Hospital, China	1.000000	0.04
Affiliated Hospital, IMMU, China	1.000000	0.04
General Hospital of Ningxia Medical University, China	1.000000	0.04
The First Hospital of Jilin University, China	1.000000	0.04
Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, China	1.000000	0.04
Pingxiang People's Hospital, China	1.000000	0.04
State Key Laboratory of Respiratory Health and Multimorbidity, China	1.000000	0.04
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	1.000000	0.04
The First Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.04
Chengdu Fifth People's Hospital, China	1.000000	0.04
The First Hospital of Qiqihar, China	1.000000	0.04
Weifang No. 2 People's Hospital, China	1.000000	0.04
Jinhua Municipal Central Hospital, China	1.000000	0.04
People's Hospital of Nanchuan, China	1.000000	0.04
Nanjing First Hospital, China	1.000000	0.04
Central Hospital of Wuhan, China	0.500000	0.02
Tongji Medical College, HUST, China	0.500000	0.02

Interested in Cardiovascular Medicine and Haematology?